Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2005; 26(02): 17-18
DOI: 10.1055/s-0041-1733115
Comments

Targeted Therapy for CML

Authors

  • Tapan K Saikia

    Prince Aly Khan Hospital,Mumbai, India
Further Information
Also available at
 PDF Download Permissions and Reprints
Preview Container


Publication History

Article published online:
28 March 2022

© 2005. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Deininger M, Buchdunger E, Druker B.J., The development of imatinib as therapeutic agent for chronic myeloid leuke¬mia, Blood 2005;105:2640-2653.
  • 2 Druker BJ Talpaz M, Resta DJ, et al, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
  • 3 Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia NEJM2003;349:1423-1432.
  • 4 Arora B, Kumar L, Kumari M, Sharma A, Wadhwa J and Kochupillai V Therapy with imatinib mesylate for chronic myeloid leukemia. Ind Jn Med & Paed Oncology2005;26:5-16.
  • 5 Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib Mesylate in chronic myeloid leuke¬mia: A prospective, single arm, non-randomized study. JAPI 2005,53.
  • 6 O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. NEJM2003;348:994- 1004.
  • 7 Gorre ME, Mohammed M, Ellwood K, et al. Clinical resis¬tance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
  • 8 Shah NP, Nicoll JM, Nagar B, et al, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the ty¬rosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
  • 9 Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003, 101:4611-4614.
  • 10 Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms ofresistance to imatinib (STI571) therapy. Leukemia, 2002;16:2190-2196.
  • 11 Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
  • 12 Bhutani M , Vora A, Kumar L & Kochupillai V. Lympho- hemopoietic malignancies in India. Med Oncol 2002;19:141- 150.